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Background: PERP (p53 apoptosis effector related to PMP-22), a transcriptional target of p53, is downregulated and contributes to
the impairment of apoptosis in uveal melanoma (UM). Intriguingly, PERP is not induced in UM despite functional p53. p63, located
on chromosome 3, which is characteristically altered in high-risk UM, can transactivate PERP. Here, we determine the functional
role of p63 expression in the initiation of p53/PERP-mediated apoptosis in UM.
Methods: PERP expression was monitored by quantitative PCR (qPCR) and immunoblotting in UM cell lines treated with DNA-
damaging agents. The functional role of p63 was assessed by transient expression of p63-turbo GFP (p63-tGFP) in the apoptosis-
resistant, 3q-deficient OCM-1 cells. Expression and localisation of p63, PERP and p53, and induction of apoptosis were
characterised by qPCR, immunoblotting and live cell confocal microscopy.
Results: PERP expression was significantly downregulated in all UM cell lines. DNA-damaging treatments failed to induce
apoptosis and activate PERP in OCM-1 cells, which displayed non-functional levels of p63. Expression of p63-tGFP induced
apoptosis with marked increase in PERP expression and associated p53 accumulation.
Conclusions: Lack of p63 contributes to reduced PERP levels and impaired p53-mediated apoptosis in UM. p63 expression is
required for PERP-mediated apoptosis in UM.
Uveal melanoma (UM) tumours of high risk have a propensity to
metastasise to the liver (Albert, 1997; Kujala et al, 2003; Kivela et al,
2006) and are characterised by chromosomal abnormalities, including
loss of chromosome 3 (monosomy 3) or partial gains of chromosome
1, 6 or 8 (Aalto et al, 2001). Despite various advancements in the
diagnosis and treatment of UM over the past few decades, disease-
related mortality is still high, with median overall mortality rate of
6 months postdiagnosis of metastasis (Triozzi et al, 2008; Spagnolo
et al, 2012). Progress in treatment is hindered by the marked
resistance of the aggressive type of UM to conventional chemotherapy
and radiotherapy. These therapeutic agents act primarily by activating
the cell death pathways. Failure to respond to these agents implies that
the resistance to apoptosis is a prominent feature of UM. Therefore,
the identification of specific molecular mechanisms underlying the
evasion of apoptosis is critical for providing the basis for targeted
approaches to eventually overcome the apoptosis resistance in UM.
Among the huge diversity of genes implicated in tumour
development, the transcription factor p53, together with its
complex signalling cascade, stands out as a master regulator of
cell survival/death pathways. Approximately 50% of human solid
tumours present direct p53 mutations and the majority of adult
cancers present impairment of the p53 signalling pathway and/or
its downstream targets (Levine, 1997; Vogelstein et al, 2000). The
latter scenario appears to be the mechanism for evasion of
apoptosis that is used by UM since there is no consistent evidence
of frequent direct p53 inactivation, mutation or altered signalling
upstream to p53 in these tumours (Brantley and Harbour, 2000;
Sun et al, 2005). The overall signalling impairment through p53
pathway (Mooy et al, 1995; Chana et al, 1999; Imesch and Albert,
1997; Brantley and Harbour, 2000) points therefore towards
functional defects downstream of p53. We have previously
identified the p53 apoptosis effector related to PMP-22 (PERP)
*Correspondence: Dr L Paraoan; E-mail: lparaoan@liverpool.ac.uk
Received 5 June 2016; revised 31 July 2016; accepted 2 August 2016
& 2016 Cancer Research UK. All rights reserved 0007 – 0920/16
FULL PAPER
Keywords: p63; apoptosis; PERP; p53; uveal melanoma; chromosome 3; monosomy 3
British Journal of Cancer (2016), 1–10 | doi: 10.1038/bjc.2016.269
www.bjcancer.com |DOI:10.1038/bjc.2016.269 1Advance Online Publication: 1 September 2016
as one such defect that has an important role in the regulation of
apoptosis in UM cells (Paraoan et al, 2006). Transcriptional
downregulation of the PERP gene was also reported in metastasis-
ing cutaneous melanoma, pancreas and mammary carcinoma cell
lines, as well as in tumours of the ovary cervix, uterus and breast
(Hildebrandt et al, 2000)
PERP was initially identified as a p53 transcriptional target that
is distinctively induced during apoptosis in response to DNA
damage or UVC treatment but not during cell cycle arrest (Attardi
et al, 2000). The expression of PERP is significantly downregulated
at the transcriptional and protein level in the aggressive, highly
metastatic monosomy 3-type UM tumours compared with disomy
3-type UM tumours (Paraoan et al, 2006). We previously showed
that induced expression of PERP is sufficient to initiate p53-
dependent apoptosis in UM cells in vitro, which involves the
upregulation of death receptor 4 or TNF-related apoptosis-
inducing ligand (TRAIL) receptor 1 and activation of caspase-8
(Davies et al, 2009). We also demonstrated that elevated PERP
expression significantly enhances the active levels of its own
transcriptional regulator, p53, which subsequently promotes
apoptosis by undergoing apoptosis-specific phosphorylation and
by transcriptionally activating specific proapoptotic genes (Davies
et al, 2011). Taken together, these studies indicate that the
endogenous levels of PERP can influence both upstream and
downstream regulation of the p53 pathway and place PERP at a
key signalling junction of p53-mediated apoptosis in UM, thus
rendering it a potential target for developing apoptosis-based
cancer therapies.
PERP contains several p53 binding sites in its promoter region
(Attardi et al, 2000; Reczek et al, 2003). However, the normal level of
p53 fails to induce PERP transcription in UM cells, suggesting that
there may be additional regulatory elements required to initiate
PERP expression either by cooperating with p53 or directly
interacting with the PERP promoter. Previous studies showed that
p53 requires its homologues p63 and p73 to induce apoptosis in
response to DNA damage (Flores et al, 2002). Indeed, the induction
of many target genes is shared among these three family members
(Jost et al, 1997; Yang et al, 1998), which are interdependent in
eliciting the apoptotic response and suppression of tumourigenesis
(Flores et al, 2002, 2005). Hence, PERP may also be transactivated
by p63 through the p53/p63 consensus element in intron 1, the
major p53-reponsive site identified in PERP (Ihrie et al, 2005).
p63, located at chromosome 3q27-29, is primarily recognised as
a global regulator of epithelial development, integrity and home-
ostasis. p63 knockout mice manifest marked absence of limbs, skin,
hair, mammary, lacrymal and salivary glands owing to failure of
these epithelia to develop during gestation (Mills et al, 1999; Yang
et al, 1999). PERP expression governed by p63 was mainly
associated with the stratified epithelium development and main-
taining the epithelial integrity by promoting desmosomal cell–cell
adhesion processes in which PERP requires direct activation by
p63 (Ihrie et al, 2005; Ihrie and Attardi, 2005). The functional
association of PERP and p63 has been extensively studied in the
context of epithelial integrity, but there is scarce information on
the possible interconnection of p63 and PERP in apoptosis. The
only such study to our knowledge is by Flores et al (2002), in which
p63 was shown to bind to PERP promoter after DNA damage in
p53 / E1A mouse embryonic fibroblasts, suggesting that p63
and p73 might regulate the ability of p53 to bind at certain selected
promoters following DNA damage.
The present study investigated for the first time the role of p63
in the PERP-mediated apoptotic pathway in UM. Our findings
indicate that lack of functional p63 (likely due to loss of
chromosome 3 in monosomy 3-type UM tumours) is a major
cause of significantly reduced PERP levels and of impairment of
p53-mediated apoptotic pathway in UM. In addition, our findings
establish that the introduction of p63 by exogenous expression
leads to significantly increased susceptibility of UM cells to
apoptosis. We present evidence that p63 expression in UM cells
results in transcriptional and translational activation of endogen-
ous PERP, which in turn drives apoptosis in UM. Finally, we show
that apoptosis caused by exogenous p63 expression requires the
activation of p53. The results provide novel insights into the
mechanisms underlying the apoptotic resistance in tumours with
reduced PERP expression.
MATERIALS AND METHODS
Cell culture. The human UM cell lines used in this study, MEL 290,
MEL285, MEL202, 92-1 and OCM-1, kindly provided by
Dr Martine Jager (University Hospital Leiden, Leiden, The Nether-
lands) (Maat et al, 2008) and Dr Dan Albert (University of Wisconsin-
Madison, Madison, WI, USA) (van Ginkel et al, 2008), were cultured
in RPMI-1640 with 2mM L-glutamine and 25mM HEPES (Gibco Life
Technologies, Paisley, UK) supplemented with 10% (v v 1)
heat-inactivated foetal calf serum (Biosera, East Sussex, UK), 1mM
sodium pyruvate and 1% (v v 1) non-essential amino acids
(Sigma-Aldrich, Dorset, UK). ARPE-19 cells (ATCC, CRL-2302,
LGC Standards, Middlesex, UK) were cultured in DMEM-F12
supplemented with L-glutamine (Sigma-Aldrich).
TRAIL and UV treatment of OCM-1 cells. Treatment with
TRAIL was carried out on subconfluent cultures (50 000 cells per
well in 12-well plates) with fresh medium at the following
concentrations: 300, 450 and 600 ngml 1. The viability of cells
treated with TRAIL was assessed using phase-contrast microscopy.
OCM-1 cells were subjected to UV irradiation at the dose of
15mJ cm 2 using CL-1000 UV crosslinker UVP. The cells were
collected and lysed at 3, 24 and 48 h post-treatment for
immunoblotting analysis.
Cell transfection. Transient transfections were carried out using a
p63-turbo GFP (p63-tGFP) expression plasmid (Origene, Rockville,
MD, USA), which encodes full-length human protein p63
(NM_003722) transcript variant 1 tagged with tGFP. OCM-1 cells
were seeded at a density of 2 105 cells per well in 6-well plates for
protein and RNA extraction and in 35-mm glass-bottomed (Iwaki,
Appleton woods, Sellyoak, Birmingham, UK) dishes for confocal
imaging. Transfections were performed with Turbofect in vitro
transfection reagent (Thermo Scientific, Paisley, UK) with 3mg of
DNA and 6.0ml Turbofect per well or per dish according to the
manufacturer’s instructions. Cells were lysed and collected for RNA
extraction and western blotting at 16, 24, 48 and 72h post-transfection.
Time-lapse cell imaging was performed 24h post-transfection.
Real-time quantitative PCR. RNA was purified using RNeasy Kit
(Qiagen Ltd, Manchester, UK). cDNA was synthesised using 1 mg
of RNA and SuperScript VILO cDNA Synthesis Kit (Invitrogen,
Paisley, UK). Real-time quantitative PCR (qPCR) was performed
with gene-specific primer sets for PERP, p63 and GAPDH
(Table 1) using a Stratagene MX3000P qPCR System (Stratagene,
La Jolla, CA, USA) and MESA Blue qPCR Kit for SYBR Green
Table 1. Gene-specific primer sets for real-time qPCR
Gene Primer sequence
Annealing
temperature (1C)
PERP 50-CCAGATGCTTGTCTTCCTGAGAG-30
50-AGTGACAGCAGGGTTGGCATGA-30
65
p63 50-CAGGAAGACAGAGTGTGCTGGT-30
50-AATTGGACGGCGGTTCATCCCT-30
65
GAPDH 50-AACAGCCTCAAGATCATCAG-30
50-TGAGTCCTTCCACGATACC-30
60
Abbreviation: qPCR¼qunatitative PCR.
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assay (Eurogentec, Southampton, UK) according to the manufac-
turer’s instructions. Genome-wide validated primer sequences
(Origene) were used to avoid any cross-amplification between p53,
p63 and p73 (which have a high degree of homology).
Laser scanning confocal fluorescence microscopy of live
transfected cells. OCM-1 cells cultured in Iwaki dishes were
transfected with p63-tGFP using Turbofect transfection reagent as
described above. Annexin-V and propidium iodide (PI) were
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Figure 1. Endogenous PERP expression in UM cells and differential response following TRAIL and UV treatment. Low PERP expression at the
(A) transcriptional and (B) protein level in all UM cell lines tested indicated downregulation of PERP in these cells. (A) endogenous PERP mRNA
levels determined by qPCR normalised to the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) are shown relative to the normalised
PERP mRNA level in ARPE19 cells (given an arbitrary value of 1). The mean of three independent experiments along with s.d. is presented.
(B) Western blot showing relative protein levels of endogenous PERP in UM cell lysates. A431 cell lysate (human epithelial carcinoma whole-cell
lysate; Abcam; ab7909) served as a positive control for the PERP antibody. (C) Differential response of OCM-1 and MEL290 cells to the TRAIL
treatment for 36 h at the concentration of 300, 450 and 600ngml 1. OCM-1 cells remained viable with normal cell morphology, even at the
highest TRAIL concentration. (D) Western blots indicating the level of PERP and DR4 proteins in OCM-1 cell lysates following treatment (36 h) with
various concentrations of TRAIL. Non-treated (NT) cells served as control for the TRAIL treatment. (E) Following UV irradiation at the dose of
15mJ cm2, OCM-1 cells were collected and lysed at 3, 24 and 48h post-treatment for immunoblot analysis using PERP antibody. UV-treated
Cos-7 cell lysate (Monkey kidney whole-cell lysate; Santa Cruz Biotechnology, Insight Biotechnology Ltd, Middlesex, UK; sc-24666) served as a
positive control. GAPDH was used as the loading control in all experiments.
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added sequentially 24 h post-transfection and live cell imaging was
performed on cells maintained in a humidified incubator (37 1C,
5% CO2) using a Zeiss LSM 510 microscope with a Fluar  20/0.75
UV objective (Carl Zeiss, Jena, Germany). Excitation of GFP was
carried out with 488-nm argon laser and emitted light was
collected through 505–550 nm bandpass filters. Propidium iodide
was excited at 543 nm with a HeNe laser and detected at 565–
615 nm, whereas the Alexa Flour 647 Annexin-V-conjugated dye
was excited at 633 nm and detected at 651–694 nm. Data
acquisition and analysis were carried out with Zeiss LSM 510
software, AIM version 3.2 (Carl Zeiss).
Determination of cell viability and apoptosis detection assay.
Apoptosis was detected by incubating the cells with Alexa Fluor
647 Annexin-V-conjugated dye (1:500 dilution) as an indicator of
early-stage apoptosis and PI (2 mgml 1) to identify cells with
lost plasma membrane integrity. Cell counts were obtained from
30 separate fields of view at 24–48 h after transfection. The
percentage of dead cells was determined for transfected or non-
transfected cells in all selected fields.
Immunoblotting. Cultured OCM-1 cells were harvested at 16, 24,
48 and 72 h after transfection with p63-tGFP and resuspended in
lysis buffer (0.128 M b-mercaptoethanol, 40mM Tris, 10% glycerol,
1% SDS and 0.01% bromophenol blue; all materials from Sigma-
Aldrich) supplemented with protease and phosphatase inhibitors
(PhoStop and cOmplete PIC; Roche, West Sussex, UK). The
proteins were separated by 12% gel electrophoresis (10% for the
detection of p63-tGFP because of its larger size, 103 kDa),
transferred to nitrocellulose membrane and probed with respective
primary antibodies: PERP (ab5986; Abcam, Cambridge, UK), p53
(P-6874; Sigma-Aldrich) and GAPDH (ab8245; Abcam). Sequen-
tial probing of the blots was carried out after incubation in
stripping solution at 65 1C for 30min, followed by 2 10min
washes in TBS-T before blocking in 5% milk/TBS-T and reprobing.
Immunocomplexes were detected with horseradish peroxidase-
conjugated secondary antibody (Sigma-Aldrich) and chemilumi-
nescence (Amersham ECL, Little Chalfont, UK). Two types of p63
antibodies were used: anti-p63 (ab53039; Abcam) detecting all
p63 proteins and anti-p63 (ab97865; Abcam) detecting the p63
transcript variant 1 (77 kDa).
RESULTS
PERP is downregulated in UM cell lines. Endogenous PERP
mRNA and protein levels were determined in five UM cell lines
(92-1, MEL202, OCM-1, MEL 285 and MEL290) and ARPE-19 (as
a non-cancer reference cell line). Levels of PERP mRNA were
reduced in all UM cell lines compared with ARPE-19 (Figure 1A).
Although some variation of PERP mRNA levels was detected
between different UM cell lines, this was not statistically
significant. The level of PERP protein was also low in all UM
cell lines consistent with the transcriptional profile of PERP gene in
these cells (Figure 1B).
PERP is not activated by TRAIL or UV treatment in UM
cells. p53 is a transcriptional regulator of PERP. PERP activation
is associated with p53-driven upregulation of DR4 and engagement
of the caspase-8 apoptotic pathway (Davies et al, 2009, 2011).
We investigated whether activation of p53 apoptotic pathways by
death-inducing ligands, such as TRAIL or UV-induced DNA
damage lead to the upregulation of PERP and subsequent
apoptosis. First, UM cell viability following treatment with TRAIL
(over the range 300–600 ngml 1) was assessed by phase-contrast
microscopy. Among all cell lines, MEL290 cells were found to be
most sensitive to TRAIL (Figure 1C). OCM-1 cells, on the other
hand, were most resistant and showed minimal cell death (o5%),
even at a dose of 600 ngml 1. Consequently, we used OCM-1
cells, which also contain marked chromosome 3 aberrations, as
a model for the aggressive type, apoptosis-resistant UM cells,
which are unresponsive to p53 pathway-targeted chemo- and
radiotherapy treatments. To further analyse whether the failure in
initiating apoptosis after TRAIL treatment is associated with lack
of upregulation of PERP, TRAIL-treated OCM-1 cells were lysed
and the level of PERP protein was determined. The treatment with
TRAIL at all concentrations tested did not lead to any increase in
the levels of either PERP or the functionally associated DR4
(Figure 1D), indicating the inability of these cells to engage
apoptotic pathways in response to these death-inducing ligands.
The expression of PERP in OCM-1 cells was also investigated
following UV irradiation. Similar to TRAIL treatment, PERP was
not induced after UV treatment (Figure 1E), indicating the lack of
response of these cells to the UV-triggered p53-dependent cell
death.
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Figure 2. p63 is significantly down-regulated in UM cell lines.
(A) Representative western blot showing relative protein levels of
endogenous p63 protein in UM cell lysates. Skin cell lysate served as a
positive control for p63 antibody. (B) mRNA was extracted from non-
transfected (NT) OCM-1 as well as from A431 cells and p63-tGFP-
transfected OCM-1 cells used as positive controls for p63 expression.
Quantitative PCR was performed to assess mRNA levels by analysing
the amplification plots and dissociation curves for each of the three
types of cells. NTC, non-template control.
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p63 is significantly downregulated in UM cell lines. The
expression of endogenous p63 protein was assessed in the same
set of UM cell lines showing undetectable levels in all with the
exception of MEL290 cells, where a faint band was detected
(Figure 2A). Notably, all these cell lines have been reported to have
several complex chromosomal aberrations, ranging from partial
deletions to the net loss of chromosome 3q in the case of OCM-1
(Luyten et al, 1996).
Considering the chromosomal location of p63 as 3q27-28 and
the net loss of 3q associated with OCM-1, these cells were further
screened for endogenous p63 mRNA expression by qPCR using
A431 cells and p63-tGFP-transfected OCM-1 as a positive control
for p63 expression. A cT value was detected in non-transfected
(NT) OCM-1 cells, indicating the presence of endogenous p63
transcript. This was, however, very high compared with A431 cells,
indicating the presence of only trace amounts of p63 mRNA in
OCM-1 cells (Figure 2B). The presence of low-level endogenous
p63 transcript in NT OCM-1 was further confirmed by the analysis
of the dissociation curve in which the single specific peak was
identified for NT OCM-1 A431 and p63-transfected OCM-1.
However, the peak height, which represents the amount of product
was significantly low in NT OCM-1. Both the high cT value and
low peak height indicated the presence of very low p63 mRNA
levels in OCM-1 cells, negligible in comparison with A431 cells
expressing full-length p63. Taken together, these results indicate
that p63 is significantly downregulated both at the transcriptional
and translational level in UM cell lines.
p63 expression induces apoptosis in UM (OCM-1) cells. To
initiate the functional studies of p63 in OCM-1 cells, we
determined the effect of induced p63 expression on cell viability.
For this purpose, cells were transiently transfected with p63-tGFP
and the cell viability assessed by Annexin-V binding and PI
staining between 24 and 48 h after transfection. Cell death was
found to be significantly higher in the cells transfected with p63-
tGFP (64.78±8.17%) compared with non-transfected cells
(26.6±2.8%), or cells transfected with GFP only (Student’s t-test,
***Pp0.0001; Figure 3A). To confirm the p63-dependent
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Figure 3. Effect of p63 expression on OCM-1 cell viability. (A) OCM-1 cells were transiently transfected with p63-tGFP and the number of viable
and nonviable cells in 10 different fields per dish (total number of fields analysed¼ 30) was counted between 24 and 48h after transfection using
Annexin- V and PI as indicators of apoptosis. The mean percentage of transfected (or non-transfected) cells dead in the transfected or NT cell
population with standard deviation from three independent transfections is shown (Students’s t-test, ***Pp0.0001) compared with GFP-only
transfected cells). (B) p63-tGFP transiently transfected OCM-1 cells were monitored through time-lapse confocal imaging for 24 h starting 24h
post-transfection, with images captured every 10min. p63-tGFP-transfected cells showing nuclear localisation of p63 undergoing apoptosis are
shown over time alongside non-transfected cells within the same cell population. (C) OCM-1 cells expressing p63-tGFP showing positive Annexin-
V binding (blue) indicate early apoptosis, whereas the PI staining (red) highlights the cells that have lost membrane integrity.
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apoptosis in real time at the single-cell level, time-lapse imaging
was performed on p63-tGFP-transfected OCM-1 cells stained with
Annexin-V and PI. The images confirmed the nuclear localisation
of p63 and onset of apoptosis in almost all p63-transfected cells in
a given field during the observation time (Figure 3B), whereas
majority of the non-transfected cells surrounding the transfected
apoptotic cells within the same cell population remained viable
with normal appearance (non-fluorescent cells; Figure 3B).
The p63-transfected apoptotic cells showed positive Annexin-V
binding (blue) and PI staining (red), thus confirming the apoptotic
characteristics of these cells (Figure 3C).
p63-led apoptosis involves transcriptional upregulation of
endogenous PERP. As PERP is an apoptotic effector and a direct
transcriptional target of p63, we tested whether PERP could be
induced by p63 during the onset of apoptosis in OCM-1 cells.
A significant increase in PERP mRNA compared with GFP control
(Student’s t-test, *Pp 0.04) was observed at 16–24 h post-
transfection when OCM-1 cells expressed p63-tGFP (Figure 4).
The pattern of PERP mRNA expression coincided with that
observed for p63 mRNA, suggesting that PERP transcription was
driven by p63 expression.
Induction of p63 expression is correlated with activation of p53-
mediated PERP apoptosis. To determine whether the observed
PERP-associated cell death following p63 overexpression involved
activation or accumulation of p53, the OCM-1 cells transiently
transfected with p63-tGFP were analysed from 16 to 72 h post-
transfection (Figure 5). After p63-tGFP expression, a clear increase
in the p53 protein level was observed after 24 h compared with
GFP-only expressing cells (paired t-test, *Pp0.02). This was also
associated with a concurrent increase in PERP levels (*Pp0.03).
The kinetics of PERP and p53 expression were both associated with
the p63 expression levels, with the maximum induction of PERP
and p53 at the time when p63 expression was at peak levels after
24 h. They then gradually reduced between 48 and 72 h. Taken
together, these data indicate that the accumulation of p53 protein
is subsequent to induction of p63 expression, which is likely to be
mediated through the positive feedback loop by which PERP
stabilises p53 (a schematic diagram of the proposed model is
presented in Figure 6) (Davies et al, 2011).
DISCUSSION
In UM, the p53 pathway is not affected through p53 mutations or
alterations of p53 protein levels, but it is functionally impaired
downstream of p53 (Kishore et al, 1996; Brantley and Harbour,
2000; Sun et al, 2005). Significant downregulation of the p53
effector PERP in primary UM tumours suggests its involvement in
a mechanism that allows these tumours to acquire resistance to
apoptosis (Paraoan et al, 2006). The signalling pathway upstream
of p53 and downstream of PERP appears to be intact and
functional in UM (Davies et al, 2009, 2011), but impairment
appears to occur at some stage between p53 and PERP, which is
unexpected as p53 is a direct transcriptional regulator of PERP
(Attardi et al, 2000). These data therefore suggest the involvement
of an additional regulator in this process.
p63 is a p53 family member that is a recognised transcriptional
regulator of PERP (Ihrie et al, 2005) and is known to cooperate
functionally with p53 in apoptosis (Yang et al, 1998; Flores et al,
2002). Importantly, p63 is located on chromosome 3 (Yang et al,
1998), where abnormalities are strongly associated with the
aggressive type (monosomy 3) of UM. Considering all these
factors, we investigated the possible role of p63 as a bridging
component between p53 and PERP in the apoptotic pathway in
UM cells. The present study demonstrates that p63 has a crucial
role in triggering apoptosis in UM cells. This process is also
mediated by restoration of transcription and translation of PERP,
which is inactive or significantly downregulated in UM primary
tumours (Paraoan et al, 2006) and in UM cell lines (current study).
Our findings suggest that p63 accomplishes its apoptotic role in a
p53-dependent manner as supported by the observation of p53
accumulation following exogenous p63 expression.
All UM cell lines used in this study displayed significantly
reduced mRNA and protein levels of PERP. This result is in line
with our previous finding of downregulation of PERP expression at
both the transcriptional and protein level in primary tumour
specimens (Paraoan et al, 2006). We previously showed that the
cell death machinery downstream of PERP that is required for
apoptosis in UM cells is responsive to a threshold level of PERP
(Davies et al, 2009, 2011), which implies that the reduced levels of
PERP observed here might not be the result of loss of
heterozygosity, but instead might be due to the absence of the
regulatory factors needed to activate PERP.
The strong positive association between PERP protein levels and
increased levels of cleaved caspase-8 forms, as well as the cleavage
of Bid protein (Davies et al, 2009), suggested that PERP might
transduce its signal through the activation of an extrinsic apoptotic
pathway. This p53-dependent pathway involves the engagement of
DR4/DR5 by ligands including TRAIL and the formation of the
death-inducing signalling complex that leads to the activation of
caspases (including caspase-8 and caspase-3), which in turn induce
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BRITISH JOURNAL OF CANCER PERP-led apoptosis requires p63 in uveal melanoma
6 www.bjcancer.com |DOI:10.1038/bjc.2016.269
1500
N
or
m
a
lis
ed
 p
63
 (1
03
 kD
a) 
pro
tei
n
de
ns
ito
m
et
er
y 
un
its
N
or
m
a
lis
ed
 P
ER
P 
(21
 kD
a) 
pro
tei
n
de
ns
ito
m
et
er
y 
un
its
N
or
m
a
lis
ed
 p
53
 (5
3 k
Da
) p
rot
ein
de
ns
ito
m
et
er
y 
un
its
p63
p53
p53
1000
500
1.5
1.0
0.5
0.0
1.5
1.0
0.5
0.0
0
GFP
NT
p63-tGFP
GAPDH
GAPDH
37 kDa
37 kDa
53 kDa
21 kDa
77 kDa
103 kDa
GFP 16 h 24 h
PERP
PERP
*
*
48 h 72 h A431
NT GFP 16 h 24 h 48 h 72 h A431
NT GFP 16 h 24 h 48 h 72 h A431
16 h PT 24 h PT 48 h PT 72 h PT
GFP 16 h PT 24 h PT 48 h PT 72 h PT
GFP 16 h PT 24 h PT 48 h PT 72 h PT
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apoptosis (Ashkenazi and Dixit, 1998). Strong induction of PERP
has also been reported in response to UVC treatment (Attardi et al,
2000). In our study, specific death-inducing stimuli for this
pathway did not induce apoptosis or alter the PERP levels in
OCM-1 cells. These findings implicate that physiological activation
of the canonical p53 apoptotic pathway alone was not sufficient to
activate PERP or induce apoptosis.
The gene encoding p63 has the chromosomal localisation of
3q 28-29. Taking into account the common abnormalities of
chromosome 3 described in UM cells, ranging from complex
rearrangements/deletions at chromosome 3q, such as in OCM-1
cells (Luyten et al, 1996; Nareyeck et al, 2006), to complete loss of a
chromosome (monosomy 3), we screened the UM cell lines for the
level/presence of p63 protein. Our results showed very low or lack
of p63, both at the transcript and protein level, suggesting the
absence of functionally active p63 protein in these cells, most likely
affected by the chromosomal abnormalities.
The role of p63 as a key player in the development and
maintenance of stratified epithelia has been extensively studied and
is widely accepted. However, the apoptotic and tumour-suppres-
sive role of p63, mainly driven by its isoforms containing
transactivation domain (TAp63), has remained more enigmatic.
Although p63 and p73 can induce apoptosis in response to DNA
damage, the notion that p53-induced apoptosis requires the
participation of p63 and p73 family members remains controver-
sial. By using the E1A programmed murine embryo fibroblasts,
Flores et al (2002) showed that the combined loss of p63 and p73
resulted in the failure of cells exhibiting functional p53 to undergo
apoptosis in response to DNA damage (Flores et al, 2002). In
another study, it was shown that the TAp63 isoform is essential in
the process of DNA damage-induced oocyte death, a process that
previously had been thought to be mediated by p53 (Suh et al,
2006). Furthermore, the induced oocyte death involved the
phosphorylation of p63 and its binding to p53 cognate DNA sites.
However, there are studies indicating that at least in thymocytes,
p53-dependent apoptosis occurs independently of p63 and p73
(Senoo et al, 2004) and that these p53 homologues are not required
for p53-mediated lymphoma suppressor activity (Perez-Losada
et al, 2005). In the present study, the OCM-1 cells displayed high
resistance towards apoptosis, despite the presence of functional
p53. The treatment with even high doses of TRAIL as well as UV
irradiation failed to induce apoptosis in OCM-1. However, these
apoptosis-resistant cells readily committed to apoptosis when p63
levels were increased following overexpression of p63. The elevated
levels of p63 induced transcription of PERP in OCM-1 cells, which
was not possible by the expression of p53 alone. These findings are
strongly supported by previous studies in which no association was
observed between p53 and PERP promoter in p63 / E1A cells in
response to DNA damage. p63 was found to bind to both the
50 and 30 binding sites on the PERP promoter (being more strongly
associated with 50 site). By contrast p53 was detected only at the
30 site. Significantly, p63 was also shown to bind to the PERP
promoter even in the absence of p53 (Flores et al, 2002).
p63 expression levels were transient in our study with a gradual
increase from 16 to 24 h, followed by a subsequent reduction.
PERP transcription was strongly associated with the expression
levels of p63 and decreased after 24 h, indicating that p63 may
function through an auto-regulatory feedback loop, in which
transcriptional activity of p63 could be directly linked with its
degradation or inhibition. Moreover, in our study, p53 and p63
displayed a similar expression profile with a transient increase
followed by a decrease in the protein levels. Given the similarities
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PERP
Nucleus
p53
p63 p53
p53
MDM2
PERP stabilises p53
(positive feedback
loop) by modulating
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transcription of
apoptotic-effector
PERP in addition to
p53.
Figure 6. Schematic representation of the involvement of p63 alongside p53 in the transcriptional regulation of PERP with role in initiation of
apoptosis in UM. PERP requires direct activation by p63, not only for cell–cell adhesion processes but also for apoptotic functions as well. As
previously shown (Davies et al, 2011), PERP expression subsequently leads to p53 stabilisation, most likely through a process involving disruption
of the interaction between p53 and its negative regulator MDM2.
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between the two proteins, they might be regulated, at least in part,
through common pathways. p53 levels are controlled in large part
by MDM2, which acts either by inhibiting the transactivation
function (Momand et al, 1992; Oliner et al, 1993) or by promoting
ubiquitin-mediated degradation (Haupt et al, 1997). MDM2 can
also bind to the N-terminus of p63 and has been variously reported
to inhibit the p63 transactivation function (Kadakia et al, 2001) or
to have no effect (Little and Jochemsen, 2001). Another mode of
inhibition has also been demonstrated for p63 through an
intramolecular mechanism. p63 a isoforms exhibit a 27 kDa
C-terminal region that is both necessary and sufficient for
transcriptional inhibition and acts by binding to the region in
the N-terminal of the TA domain of p63 that is homologues to
MDM2 binding site in p53, hence masking residues that are
important for transactivation (Serber et al, 2002).
In summary, this study highlights for the first time the p63
requirement for initiation of apoptosis in UM and provides the
experimental evidence of its essential function alongside p53 in the
PERP-mediated apoptosis. Although our findings do not diminish
the significance of p53 in this process, they do underscore the
importance of p63 in the p53-dependent apoptotic and tumour-
suppressive function of PERP. Furthermore, the findings provide
for the first time a functional link between a molecular determinant
(p63) highly likely to be affected by the well-described alterations
of chromosome 3 in UM and the pathogenesis of this tumour. The
findings have also broad-ranging implications for other cancers in
which similar overall dysfunction of p63 may underlie the
regulation of apoptosis effectors such as PERP and the impaired
ability of tumour cells to engage in apoptosis. Such insights are
expected to prove advantageous in designing therapeutic
approaches for increasing susceptibility to apoptosis required
to overcome the tumour resistance to chemotherapy and
radiotherapy.
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